Drugs / NH102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07324408 | Mar 2022 → Apr 2023 | depressive disorder | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05015192 | Aug 2021 → Jan 2022 | depressive disorder | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06842992 | Dec 2024 → Jul 2025 | major depressive disorder | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NH102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05015192 ↗ |
| Route | Oral | “NH102 3mg, tablet, orally, once on Day 1” NCT05015192 ↗ |